Almac Clinical Services marked the start of 2010 with the official launch of a new web-based, Shipping Temperature Electronic Monitoring System - stems.
Temperature excursions can inhibit the clinical supply chain, resulting in crucial investigational products being delayed or quarantined and not made available for immediate use at the study site. Excursions can occur at any point in a global supply chain and often arise as a result of multiple uncontrollable factors.
Upon download, Almac’s Shipping Temperature Electronic Monitoring System – stems, equips clinical supply professionals with immediate visibility over all crucial shipment temperature reports. This enables users to make instant decisions 24/7 on their clinical supplies.
Stems is the latest addition to the Almac services portfolio for temperature controlled clinical supplies. Alongside the Group’s Specialist Temperature Controlled Team, and customised shipping unit systems, this new technology delivers the following key features:
Key Features
–100% shipping temperature reports
– improved inventory management
– compliant with 21 CFR Part 11 requirements
This latest launch also coincides with a new Label Approval System (LAS) – a workflow-based label approval management system. LAS gives users full online review, amendment, traceability and control functionality.
Martin Lamb, Vice President of Global Business Development, Almac Clinical Services commenting on the launch of the new system: “I am delighted to announce the launch of our new Shipping Temperature Electronic Monitoring System - stems. We have experienced rapid growth in the volume of our controlled temperature shipments in the past few years. Improving visibility and performance in this area is a key goal for Almac, our clients and regulators alike, so the introduction of new, innovative tools has been a core part of our business strategy. By helping our clients achieve these goals, stems will be of major interest to Pharmaceutical and Biotech clients.’
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.